TY - JOUR
T1 - Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von „Renale-Denervations-Zentren (RDZ)“ – Update
AU - Mahfoud, Felix
AU - Galle, Jan
AU - Schunkert, Heribert
AU - Schmieder, Roland E.
AU - Rump, Lars C.
AU - Limbourg, Florian P.
AU - van der Giet, Markus
AU - Elsässer, Albrecht
AU - Kintscher, Ulrich
AU - Böhm, Michael
AU - Weil, Joachim
N1 - Publisher Copyright:
© 2021, Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e.V. Published by Springer Medizin Verlag GmbH, ein Teil von Springer Nature - all rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Arterial hypertension is highly prevalent and remains the most common modifiable risk factor for cardiovascular morbidity and mortality worldwide. In the development and progression of uncontrolled hypertension an increased sympathetic nerve activity has been identified as a main contributor. Catheter-based renal denervation was developed to selectively modulate renal sympathetic activity. Recently, several randomized sham-controlled trials have proven the efficacy and safety of renal denervation in patients with uncontrolled hypertension. Hence, one may expect renal denervation to be used as part of clinical practice some time soon. This paper aims to define national criteria for centers who wish to perform renal denervation procedures and to optimize care pathways for patients with uncontrolled hypertension. Centers may apply for certification once they fulfill all criteria.
AB - Arterial hypertension is highly prevalent and remains the most common modifiable risk factor for cardiovascular morbidity and mortality worldwide. In the development and progression of uncontrolled hypertension an increased sympathetic nerve activity has been identified as a main contributor. Catheter-based renal denervation was developed to selectively modulate renal sympathetic activity. Recently, several randomized sham-controlled trials have proven the efficacy and safety of renal denervation in patients with uncontrolled hypertension. Hence, one may expect renal denervation to be used as part of clinical practice some time soon. This paper aims to define national criteria for centers who wish to perform renal denervation procedures and to optimize care pathways for patients with uncontrolled hypertension. Centers may apply for certification once they fulfill all criteria.
KW - Devise-based hypertension treatment
KW - Renal denervation
KW - Renal nerve ablation
KW - Resistant hypertension
UR - http://www.scopus.com/inward/record.url?scp=85110928245&partnerID=8YFLogxK
U2 - 10.1007/s12181-021-00492-7
DO - 10.1007/s12181-021-00492-7
M3 - Übersichtsartikel
AN - SCOPUS:85110928245
SN - 1864-9718
VL - 15
SP - 463
EP - 470
JO - Kardiologe
JF - Kardiologe
IS - 5
ER -